MobbleOpen in Mobble ⇢
Health · Drug development · published 2026-10-19 · via Psychiatric Times

Phase 2 Trial Reports Symptom Gains With Bezisterim in Long COVID

Image via Psychiatric Times
Image via Psychiatric Times

A phase 2 trial assessed bezisterim as a treatment for long COVID. The drug showed safety and symptom improvements, with the strongest benefits reported for severe fatigue, post-exertional malaise, and cognitive issues.

Expanded Detail

A mid-stage study tested bezisterim in people with long COVID and reported that it was safe while symptoms improved. The largest gains were described for severe fatigue, post-exertional malaise, and cognitive problems. Long COVID can involve lasting symptoms, and researchers continue to seek treatments. These findings are early and would need confirmation before they could change care.

Context

If confirmed, a treatment that improves long COVID symptoms could affect people with persistent fatigue, post-exertional malaise, and cognitive difficulties, along with their caregivers, workplaces, and health services. It may influence clinical conversations and research priorities. Because the evidence comes from a phase 2 trial, broader societal effects would depend on larger studies and regulatory decisions.

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at Psychiatric Times →
Related stories
First Human Trial of Partial Epigenetic Reprogramming Reports Early Safety Data · Aging & longevity
Gilead oral IBD therapy clears symptoms in Phase 2 trial · Drug development
Gilead oral drug shows higher ulcerative colitis remission than Entyvio in Phase 2 · Drug development
Disc Medicine’s rare sun-pain therapy succeeds across Phase 3 endpoints · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “New Phase 2 Data on Bezisterim for the Treatment of Long COVID.” Browse more stories.